open access

Vol 56, No 2 (2005)
Original papers
Published online: 2006-03-24
Submitted: 2013-02-15
Get Citation

The effect of primary lack of estrogens and the influence of the age at the beginning of estrogen therapy on bone mineral density in patients with Turner’s syndrome

Elżbieta Sowińska-Przepiera, Elżbieta Andrysiak-Mamos, Zbigniew Friebe, Karina Kapczuk, Krystyna Pilarska
Endokrynologia Polska 2005;56(2):145-153.

open access

Vol 56, No 2 (2005)
Original papers
Published online: 2006-03-24
Submitted: 2013-02-15

Abstract

Lumbar spine bone mineral density (BMD) values were measured in women with Turner’s syndrome (TS) and the influence of primary ovarian failure as well as the age at the start of estroprogestins (EP) therapy were considered. EP treatment with 2mg of estradiol (E2) and BMD monitoring were started in 72 and finally continued for 5 years in 34 patients with TS, aged 12-38 years, previously not treated with growth hormone or anabolic steroids. The mean total BMD gain (∆BMD) was 20% and the most significant increase was observed after the first (7.5%) and the second (6.6%) year of the therapy. Before the start and during EP treatment E2 levels were evaluated: they increased from 9.2pg/ml to the values observed in the controls (C) but positive correlation with BMD was not observed. Analysis of TS patients in age brackets (<15 years, 15-20 years, 21-25 years, >25 years) showed that only in the group that started EP treatment before the age of 15 every year significant ∆BMD was observed. The group that started EP therapy after the age of 20 didn’t achieve significant ∆BMD. Patients wit TS had significantly higher levels of bone metabolism markers (Ntx and BALP) than the controls and in both groups negative correlation with age was found. On the basis of the results the conclusion was made that in hypoestrogenic women, not exclusively TS, the age when estrogen therapy is started may determine the effects in relation to bone mass. The administered E2 doses may also be important.

Abstract

Lumbar spine bone mineral density (BMD) values were measured in women with Turner’s syndrome (TS) and the influence of primary ovarian failure as well as the age at the start of estroprogestins (EP) therapy were considered. EP treatment with 2mg of estradiol (E2) and BMD monitoring were started in 72 and finally continued for 5 years in 34 patients with TS, aged 12-38 years, previously not treated with growth hormone or anabolic steroids. The mean total BMD gain (∆BMD) was 20% and the most significant increase was observed after the first (7.5%) and the second (6.6%) year of the therapy. Before the start and during EP treatment E2 levels were evaluated: they increased from 9.2pg/ml to the values observed in the controls (C) but positive correlation with BMD was not observed. Analysis of TS patients in age brackets (<15 years, 15-20 years, 21-25 years, >25 years) showed that only in the group that started EP treatment before the age of 15 every year significant ∆BMD was observed. The group that started EP therapy after the age of 20 didn’t achieve significant ∆BMD. Patients wit TS had significantly higher levels of bone metabolism markers (Ntx and BALP) than the controls and in both groups negative correlation with age was found. On the basis of the results the conclusion was made that in hypoestrogenic women, not exclusively TS, the age when estrogen therapy is started may determine the effects in relation to bone mass. The administered E2 doses may also be important.
Get Citation

Keywords

osteoporosis; Turner’s syndrome; bone mineral density; estrogen replacement

About this article
Title

The effect of primary lack of estrogens and the influence of the age at the beginning of estrogen therapy on bone mineral density in patients with Turner’s syndrome

Journal

Endokrynologia Polska

Issue

Vol 56, No 2 (2005)

Pages

145-153

Published online

2006-03-24

Bibliographic record

Endokrynologia Polska 2005;56(2):145-153.

Keywords

osteoporosis
Turner’s syndrome
bone mineral density
estrogen replacement

Authors

Elżbieta Sowińska-Przepiera
Elżbieta Andrysiak-Mamos
Zbigniew Friebe
Karina Kapczuk
Krystyna Pilarska

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl